<DOC>
	<DOCNO>NCT00660881</DOCNO>
	<brief_summary>The primary objective study assess safety epratuzumab patient SLE .</brief_summary>
	<brief_title>Open-label Study Epratuzumab Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>SL0007 patient complete week 12 study early terminate week 8 later due treatment failure Patients must maintain eligibility requirement throughout participation SL0007 Written inform consent sign prior initiation studyspecific assessment visit 1 Patients may receive live vaccination within 2 week prior visit 1 course study Active severe SLE disease activity involve CNS system ( defined BILAG neurologic A level activity ) include transverse myelitis , psychosis seizure Active severe SLE disease activity involve Renal system ( defined BILAG renal level A activity Grade III high WHO nephritis ) serum creatinine &gt; 2.5mg/dL clinically significant serum creatinine increase within prior 4 week proteinuria &gt; 3.5gm/day Patients history antiphospholipid antibody syndrome AND Use oral anticoagulant antiplatelet treatment Patients history chronic infection , recent significant infection , current sign symptom may indicate infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>B-Cell immunotherapy</keyword>
</DOC>